Genmab Other Non-Current Liabilities 2019-2024 | GMAB

Genmab other non-current liabilities for the quarter ending September 30, 2024 were $0.004B, a 13.88% decline year-over-year.

  • Genmab other non-current liabilities for 2023 were $0.005B, a 226.19% increase from 2022.
  • Genmab other non-current liabilities for 2022 were $0.002B, a 24.66% decline from 2021.
  • Genmab other non-current liabilities for 2021 were $0.002B, a 169.97% increase from 2020.

Genmab Other Non-Current Liabilities 2019-2024 | GMAB

  • Genmab other non-current liabilities for 2023 were $0.005B, a 226.19% increase from 2022.
  • Genmab other non-current liabilities for 2022 were $0.002B, a 24.66% decline from 2021.
  • Genmab other non-current liabilities for 2021 were $0.002B, a 169.97% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$174.8B
Vertex Pharmaceuticals (VRTX)$133.1B
Gilead Sciences (GILD)$120.2B
Bristol Myers Squibb (BMY)$109.8B
Regeneron Pharmaceuticals (REGN)$91B
CSL (CSLLY)$90.5B
GSK (GSK)$75.2B
Alnylam Pharmaceuticals (ALNY)$35.8B
Argenex SE (ARGX)$35.6B
BioNTech SE (BNTX)$26.3B
Biogen (BIIB)$25.2B
Illumina (ILMN)$24B
BeiGene (BGNE)$20B
Moderna (MRNA)$18B
Incyte (INCY)$16.1B
Vaxcyte (PCVX)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$12.8B
Bio-Techne Corp (TECH)$12.1B
Sarepta Therapeutics (SRPT)$11.6B
Exelixis (EXEL)$10.4B
Revolution Medicines (RVMD)$10.2B
QIAGEN (QGEN)$10B
Intra-Cellular Therapies (ITCI)$9.7B
Exact Sciences (EXAS)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.8B
Repligen (RGEN)$7.9B
Halozyme Therapeutics (HALO)$7.8B
Viking Therapeutics (VKTX)$7.6B